Neurotech International (ASX:NTI) secured approval from the Human Research Ethics Committee to conduct a pharmacokinetic study of cannabis-based drug candidate NTI164 in healthy human adults at the CMAX Clinical Research in South Australia, according to a Monday filing with the Australian bourse.
NTI164 is a drug formulation derived from a cannabis strain with low tetrahydrocannabinol content and a combination of cannabinoids, the filing said.
The proposed trial, which follows a pediatric study in neurological disorders, aims to produce clinical data on the metabolism and excretion of NTI164 in the adult human population, according to the filing. It is set to start in the current quarter, with results expected in the first quarter of next year.
Shares rose nearly 8% in afternoon trade Tuesday.
Price (AUD): $0.07, Change: $+0.01, Percent Change: +7.58%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。